Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete. Recruitment is ongoing at sites located around the world, including in the U.S., where sites are ready to enroll eligible patients.

The TRUST trial is designed to evaluate the safety and efficacy of the investigational compound BAY 86-6150, a recombinant factor VIIa (rFVIIa) protein in patients with hemophilia A or hemophilia B who have developed neutralizing antibodies, called inhibitors.

"Bayer is committed to finding innovative ways to meet the needs of people with hemophilia, including those affected by the effects of inhibitors to clotting factor replacement therapies," said Pamela Cyrus, MD, Vice President and Head, U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals.

SOURCE Bayer HealthCare Pharmaceuticals Inc.